Creacion Ventures

Sirius Therapeutics is a biotechnology company specializing in the development of RNA interference (RNAi) therapies. It focuses on treating chronic cardiovascular diseases, providing innovative solutions for both physicians and patients.

Frontera Therapeutics is a biotechnology company dedicated to developing and commercializing recombinant virus-based gene therapies. Its mission is to establish an affordable and scalable platform for producing high-quality rAAV therapies, targeting genetic disorders such as those affecting the eye, liver, metabolism, and neuromuscular systems.

Founded in 2019 and based in Cambridge, Massachusetts, MoMa Therapeutics discovers precision medicines by targeting molecular machines underlying human diseases. The company's platform enables drug development from previously intractable enzyme classes.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.

Pediatrix Therapeutics specializes in pediatric pharmaceuticals, focusing on developing and distributing effective, clinically proven children's medicines. Its mission is to provide high-quality, affordable treatment options for Chinese children and families.

Founded in 2019 and based in Cambridge, Massachusetts, MoMa Therapeutics discovers precision medicines by targeting molecular machines underlying human diseases. The company's platform enables drug development from previously intractable enzyme classes.

Sirius Therapeutics is a biotechnology company specializing in the development of RNA interference (RNAi) therapies. It focuses on treating chronic cardiovascular diseases, providing innovative solutions for both physicians and patients.